![Mark Payton](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mark Payton
Directeur Général chez Caldan Therapeutics Ltd.
Postes actifs de Mark Payton
Sociétés | Poste | Début | Fin |
---|---|---|---|
Caldan Therapeutics Ltd.
![]() Caldan Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Caldan Therapeutics Ltd. provides novel therapeutics targeting free fatty acid. It focuses on developing drugs in order to deliver anti-diabetic effects in multiple tissues and organs. The company was founded by Graeme Milligan and Trond Ulven and is headquartered in Edinburgh, the United Kingdom. | Directeur Général | 08/03/2017 | - |
Président | - | - |
Historique de carrière de Mark Payton
Anciens postes connus de Mark Payton
Sociétés | Poste | Début | Fin |
---|---|---|---|
Celentyx Ltd.
![]() Celentyx Ltd. BiotechnologyHealth Technology Celentyx Ltd. provides research and development on human immune disease. The firm's services include rapid analysis screening of drug action on physiological and pathological human immune tissues and cells. It provides services by disease, cell type, assay through its ImmuKnowlogy platform technology. The company was founded by Nicholas Mark Barnes and John Gordon in 2004 and is headquartered in Birmingham, the United Kingdom. | Directeur/Membre du Conseil | - | - |
Biogen MA, Inc.
![]() Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
GSK PLC | Corporate Officer/Principal | - | - |
Oxagen Ltd.
![]() Oxagen Ltd. Pharmaceuticals: MajorHealth Technology Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | 09/08/2011 | - |
Directeur Général | 01/07/2002 | - | |
Directeur Technique/Scientifique/R&D | 01/07/2002 | - |
Formation de Mark Payton
The University of Sheffield | Undergraduate Degree |
University of Leicester | Doctorate Degree |
Statistiques
Internationale
Royaume-Uni | 7 |
Etats-Unis | 2 |
Opérationnelle
Director/Board Member | 2 |
Chief Executive Officer | 2 |
Corporate Officer/Principal | 2 |
Sectorielle
Health Technology | 5 |
Consumer Services | 3 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
GSK PLC | Health Technology |
Entreprise privées | 4 |
---|---|
Oxagen Ltd.
![]() Oxagen Ltd. Pharmaceuticals: MajorHealth Technology Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom. | Health Technology |
Biogen MA, Inc.
![]() Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
Celentyx Ltd.
![]() Celentyx Ltd. BiotechnologyHealth Technology Celentyx Ltd. provides research and development on human immune disease. The firm's services include rapid analysis screening of drug action on physiological and pathological human immune tissues and cells. It provides services by disease, cell type, assay through its ImmuKnowlogy platform technology. The company was founded by Nicholas Mark Barnes and John Gordon in 2004 and is headquartered in Birmingham, the United Kingdom. | Health Technology |
Caldan Therapeutics Ltd.
![]() Caldan Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Caldan Therapeutics Ltd. provides novel therapeutics targeting free fatty acid. It focuses on developing drugs in order to deliver anti-diabetic effects in multiple tissues and organs. The company was founded by Graeme Milligan and Trond Ulven and is headquartered in Edinburgh, the United Kingdom. | Commercial Services |
- Bourse
- Insiders
- Mark Payton
- Expérience